Investors hope Nvidia makes a statement
And then DeepSeek, the Chinese artificial intelligence pricked the bubble, saying it could develop large language models for artificial intelligence at lower costs than Nvidia.
Tariffs became a really big problem.
💵💰 💰💵
There were administration crackdowns on sales of Nvidia's not-quite top of the line H20 Graphic Processing Units to Chinese customers.
And, suddenly, Nvidia hit a closing of low of $96.30 on April 8, down 28.3% on the year.
The slump probably had more to do with the market reaction to President Trump's tariff plan than anything Nvidia had done.Now, almost six weeks later, Nvidia shares are back up to $131.29. That's up 36% in a bit more than a month but still down 2.2% since Dec. 31 and 14.3% from the Jan. 7 high.
After Wednesday's close, Nvidia, a component of the Dow Jones Industrial Average, will report fiscal-first-quarter results, and they will get plenty of attention.
The consensus estimate is Nvidia will report earnings of 73 cents a share, up 16% from a year ago, and revenue of $43.4 billion, up 66% from a year ago.
The earnings estimate has come down from 93 cents 60 days ago.
But many investors are hopeful that Nvidia has weathered the DeepSeek storm, maybe found a way to create products that will win U.S. government export licenses necessary to sell to customers in China and can get stock moving again.
The company's market capitalization is back to $3.2 trillion, behind Microsoft () at $3.25 trillion and ahead of Apple () at $2.92 trillion.
Maybe Nvidia will deliver, as the company basically did in the last quarter. And maybe investors will reward their efforts.
Futures trading late Sunday suggests U.S. stocks will rebound from Friday's slump when trading reopens on Tuesday. U.S. financial markets will be closed Monday for Memorial Day.
The uptick looks like a relief rally after President Trump disclosed Sunday he had agreed to a European request to delay 50% tariffs until at least July 9.
(There is a school of thought making its way through Wall Street that July 9 might not be a hard deadline.)In a holiday-shortened week, investors will deal with a broad swath of earnings reports.
Among other tech companies expected to report are:
Salesforce () , the big customer relations management company (and a Dow component, like Nvidia), due after Wednesday's close.
Dell Technology () , after Thursday's close.
Marvell Technology () , after Thursday's close.
Cloud security company Zscaler () after Thursday's close.
Software company Synopsys () .
HP Inc. () , after Wednesday's close.
The week includes a heavy dose of tech earnings and results from one giant retailer: Costco Wholesale () , due after Thursday's close.
Costco is the third largest retailer by market cap (at $448 billion), behind Amazon.com AMZN (at $2.13 trillion) and Walmart () (at $771 billion).
Costco is expected to report earnings of $4.21 a share, up 11.4% from a year ago. The revenue projection is $62.9 billion, up 7.4% from a year. The shares are up 10.1% in 2025.
Fund manager buys and sells
Fund manager who forecast stock drop and pop talks what's next
Fund manager sends blunt message on S&P 500 bear market risk
Fund manager resets stock market forecast after oversold rally
In addition to Costco, retailers reporting this week include:
AutoZone () , before Tuesday's open.
DICK's Sporting Goods () , before Wednesday's open.
Macy's () , before Wednesday's open.
The Gap () , after Thursday's close.
Burlington Stores () , before Thursday's open.
Ulta Beauty () , after Thursday's close.
Shoe retailer Foot Locker () , before Thursday's open.
If the tariff rhetoric can be toned down from last week, it might be a decent week.
The S&P 500 was off 2.5% on the week. The Dow and Nasdaq Composite fell 2.5%, and the Russell 2000 Index fell 3.5%.
Interest rates will be a big question. The 10-year Treasury yield ended last week at 4.52%. That keeps mortgage rates relatively high and consumer confidence on edge.Investors hope Nvidia makes a statement first appeared on TheStreet on May 26, 2025

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Cardinal Health expands urology focus with $1.9bn Solaris Health deal
US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio
Yahoo
16 minutes ago
- Yahoo
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut
President Donald Trump has signaled he may be open to letting Nvidia (NASDAQ:NVDA) ship a toned-down version of its most advanced Blackwell AI chip to China if the company trims its capabilities by 30% to 50%. The comment comes shortly after Trump confirmed an unusual arrangement already in place for Nvidia's less-powerful H20 chip, which allows exports to China in exchange for a 15% revenue share paid directly to the US government. Advanced Micro Devices will follow the same formula for its MI308 chip, according to a person familiar with the matter. Nvidia has not commented on the president's remarks. Warning! GuruFocus has detected 5 Warning Signs with NVDA. The potential deal for Blackwell would mirror Trump's broader push to secure financial returns for the US in exchange for loosening certain export restrictions a strategy that could influence how American companies negotiate market access in China. While Trump didn't outline a specific timeline, he suggested Nvidia CEO Jensen Huang could soon meet with him to discuss a negatively enhanced Blackwell variant. If approved, the move could mark a shift in how high-end US chip technology is selectively offered abroad. Nvidia's Blackwell chips are the backbone of today's most powerful AI systems but remain off-limits to China under current US rules. Both Nvidia and AMD (NASDAQ:AMD) have taken revenue hits as tighter controls limited exports to older models on par with domestic Chinese alternatives products that have struggled to gain traction. Nvidia has already said it is developing another China-specific chip and will seek approval to sell it. The company noted that further cutting back its Hopper-based H20 chip is no longer viable, suggesting a modified Blackwell could be the clearest path to regaining momentum in one of the world's largest AI markets. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data